and Gore on the use of thrombolytic therapy in patients with acute myocardial infarction [1] . The authors note the history and vicissitudes of the notion that myocardial infarction is caused by coronary thrombosis and set forth the concept of the limitation of infarct size. In addition, the authors review the elements of the fibrinolytic system and its perturbations caused by conventional and new thrombolytic agents. Finally, they summarize the results of clinical investigative work carried out in Europe and North America involving clotdissolving drugs in patients with acute myocardial infarction.
Coronary heart disease is a major public health problem in the United States. Six million patients have symptomatic coronary disease, and many more have clinically silent, progressive coronary atherosclerosis. Each year in the United States approximately 680,000 patients from both the symptomatic and the clinically silent populations suffer acute myocardial infarction, most through the intermediate step of coronary thrombosis, and survive long enough to be hospitalized [2] . Diagnosis and treatment begins with the emergency medical system (i.e., ambulance crews or emergency ward personnel), followed by admission to a coronary care unit. Conventional treatment is essentially passive, consisting of bed rest, oxygen supplementation, relief of pain by narcotics, and careful monitoring of heart rhythm and vital signs to permit early diagnosis and treatment of complications such as ventricular fibrillation, congestive heart failure, and heart block or shock. As noted in the review, there is mounting evidence that prompt administration of thrombolytic agents to patients with acute myocardial infarction reduces short-term mortality. The earlier treatment is given, the greater the observed effect. Effective future management of patients with acute myocardial infarction will require an even closer integration of the specialties of emergency medicine and cardiology if this advance is to be fully exploited. I now attempt to present briefly the elements supporting the switch from passive to active management of patients with acute myocardial infarction.
Careful clinical investigation over the past two decades has documented that conventionally treated patients with myocardial infarction lose highly variable amounts of myocardium. In addition, both length of survival and quality of life in patients with myocardial infarction is inversely related to the size of the infarction: The larger the infarction, the worse the outlook for both survival and quality of life. The variability in infarct size and , its relation to outcome have led to investigative efforts to ascertain whether it is possible to manipulate infarct size pharmacologically in the experimental laboratory and in clinical investigation [3] . Although a number of drugs have produced promising reductions of infarct size in the laboratory, the results in patients have not been persuasive until recently, when attention turned to thrombolytic agents.
The time course of myocardial necrosis after coronary occlusion has been carefully charted. In the experimental laboratory canine myocardium jeopardized by placement of a coronary ligature is completely necrotic after six hours; coronary ligature removal less than 20 minutes after closure results in no demonstrable necrosis. In the canine model myocardial necrosis begins at the endocardium and proceeds toward the epicardium over the next four to six hours [4] . The time course of myocardial necrosis in humans with chronic coronary artery disease has not been clearly delineated, but it probably resembles closely the time course observed in canine models. Thus, interventions designed to limit the amount of myocardial damage in patients with acute myocardial infarction must be applied soon after the onset of chest pain.
A large number of clinical trials followed the introduction of the first thrombolytic agents in the late 1950s. These trials were carried out in North America and Europe and resulted in confusing and, at times, contradictory results [5] . The direct arteriographic demonstration by Rentrop in 1979-that most patients with acute myocardial infarction have complete coronary occlusion and that intracoronary streptokinase opened the majority of these closed coronary arteries-led to renewed interest in this form of therapy [6] . It is clear, based on a rather large number of case series, that 80% of patients with acute transmural myocardial infarction have closed coronary arteries, and that between 70 and 80% of these closed arteries will open with direct coronary instillation of streptokinase. However, coronary arteriography requires a cardiac catheterization laboratory staffed by an expert team. Given the availability of such a laboratory and team, the delay in delivery of intracoronary thrombolytic drugs is at least an hour, more likely two to three hours. The procedure is costly, uncomfortable, and imposes substantial delay at a time when the curve relating elapsed time from the onset of myocardial infarction and the total amount of myocardial necrosis is particularly steep. Thus, investigative interest in the last several years has focused on the use of intravenous thrombolytic agents, most often streptokinase or urokinase and, more recently, a series of new drugs.
A new generation of more fibrin-specific plasminogen activators, such as tissue-plasminogen activator, has recently become available in sufficient quantities for clinical trial. This clot-specific thrombolytic agent is chemically drawn to thrombus, is a poor activator of plasminogen in the absence of clot, and, based on two large comparative studies in Europe and the United States, is roughly twice as effective as intravenous streptokinase in opening closed coronary arteries in patients with acute myocardial infarction [7, 8] .
Early in 1986 a large trial study of intravenous streptokinase found an 18% reduction in hospital mortality among patients randomly selected to receive 1.5 million units of streptokinase infused over an hour compared with patients treated conventionally [9] . This mortality reduction was more marked in patients treated within a few hours of myocardial infarction, particularly within one hour. A second recent trial compared the use of intravenous streptokinase followed by intracoronary streptokinase with conventional therapy for acute myocardial infarction; a reduction in both 28-day and one-year mortality was demonstrated in patients treated with streptokinase [10]. A third, double-blind randomized trial using 1.5 million units of streptokinase compared with placebo reported a similar modest reduction in mortality that was not statistically significant [11] . Finally, an analysis of a number of trials using intravenous thrombolytic drugs, either streptokinase or urokinase, revealed a pooled estimate of a 20% reduction of early mortality [5] . These results in aggregate make a compel-ling case for the use of intravenous thrombolytic therapy in patients with acute myocardial infarction.
Thrombolytic therapy is a major advance in the treatment of patients with myocardial infarction. This therapy is most effective when delivered within a few hours of myocardial infarction; this will impose substantial strains on emergency medical systems. In addition, it is quite likely that additional therapy in the form of antiplatelet or anticoagulant drugs or mechanical therapy such as PTCA or coronary artery bypass graft (CABG) surgery will be needed in subsets of these patients, because follow-up angiography in patients treated with intravenous thrombolytic drugs often reveals high-grade coronary stenosis, predisposing the patient to recurrent episodes.
In summary, early administration of thrombolytic therapy to patients with acute myocardial infarction appears to result in reduced in-hospital mortality. It is likely that additional therapy will be required in subsets of patients so treated to preserve and extend the effect of the inicial thrombolytic therapy. Clinical investigative work in the next 5 to 10 years will focus on (1) refining thrombolytic therapy by such means as free radical scavengers to limit reperfusion damage and (2) careful examination of patients to select those who require additional therapy in the form of PTCA or CABG surgery. The practical implications of this work are immense. This mode of therapy is a milestone in the development of more effective therapies for this major public health problem. 
